Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

176.88 +2.06 (+1.18%)
Streaming Delayed Price Updated: 12:14 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,938
Open 175.73
Bid (Size) 176.84 (100)
Ask (Size) 176.94 (100)
Prev. Close 174.82
Today's Range 175.37 - 177.14
52wk Range 110.03 - 185.17
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers. 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
+17.9%
+17.9%
1 Month
+0.0%
+0.0%
3 Month
+27.0%
+27.0%
6 Month
+40.0%
+40.0%
1 Year
+18.4%
+18.4%

More News

Read More
News headline image
Biogen (BIIB) Stock Trades Up, Here Is Why
Via StockStory
Topics Artificial Intelligence Economy
News headline image
$7 Trillion "Witching Hour": Unprecedented Derivatives Expiration Sparks Volatility on Wall Street
Via MarketMinute
Topics Derivatives Economy Regulatory Compliance
News headline image
1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds
Via StockStory
News headline image
3 Healthcare Stocks We Think Twice About
Via StockStory
Topics Stocks
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗
Via The Motley Fool
News headline image
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
Via MarketMinute
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
News headline image
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy Government World Trade
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 176.88
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 12/24/25 12:14 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 25.79B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.